Form 4: Director Samit Hirawat Receives Pacira Equity Grant
Statement of Changes in Beneficial Ownership
Pacira BioSciences Director Samit Hirawat was granted 6,405 restricted stock units and 10,891 stock options on June 10, 2026.
Summary
- Director Samit Hirawat acquired 6,405 restricted stock units (RSUs) as part of an equity compensation grant.
- The director also received a stock option grant for 10,891 shares with an exercise price of $23.42.
- Both the RSUs and the stock options are subject to a one-year vesting period, becoming exercisable on June 10, 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices rather than a change in company strategy or financial performance.
Positives
- Equity grants align the interests of the director with those of shareholders.
- The grants are subject to continued service, incentivizing long-term retention of board leadership.
Negatives
- The issuance of new equity results in minor dilution to existing shareholders.
Risks
- Vesting is contingent upon the director remaining in continuous service with the issuer.
Future Outlook
The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director equity compensation.
Industry Context
StockSavvy.ai notes that standard equity grants for board members are common practice in the biotechnology sector to ensure alignment between independent directors and corporate performance goals.
Comparison to Industry Standards
- The use of a one-year cliff vesting schedule for director equity is consistent with standard corporate governance practices for mid-cap biotechnology firms.
- The combination of RSUs and stock options is a typical compensation structure for board members in the life sciences industry.
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Vesting of equity awards on June 10, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/10/2026 | Date of the equity grant transaction. |
| 06/12/2026 | Date the Form 4 was filed with the SEC. |
| 06/10/2027 | Vesting date for both the RSUs and the stock options. |
| 06/10/2036 | Expiration date for the stock options. |
Keywords
Pacira BioSciences, PCRX, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.